Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium is an HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet to: Reduce the risk of MI,revascularization, andcardiovascularmortalityin hypercholesterolemicpatientswithout clinicallyevidentCHD.